Logo

MedReleaf ReleafDx

Nov 09, 2017

Canadian medical cannabis firm MedReleaf is launching in that country ReleafDx, a genetic test to help physicians in the prescription of cannabis. Based on a cheek swab, the test analyzes a patient's DNA and health conditions, providing information that a doctor can use to determine what cannabis product will work best for an individual, and the proper dosage. Dynacare, a Laboratory Corporation of America company, will manage the sample analysis and results reporting. The cheek swab can be done in doctors' offices or at a Dynacare Laboratory and Health Services Centre. The samples are then sent to Dynacare for analysis. Results are returned to the doctor with recommendations on the proper dosage of medReleaf's products. The test will be available in Canada starting in January.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.